HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary sharesHKPD
HKPD
About: Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
–
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for HKPD.
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
U.S. IPO Weekly Recap: Oil And Gas Well Equipment Provider Flowco Debuts, While More Sizable Deals Join The Pipeline
Three IPOs and three SPACs were listed this week. Eight issuers submitted initial filings this week, including a handful of sizable names. The US IPO market is set to host a historic event in the week ahead.

Neutral
PRNewsWire
1 month ago
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ: HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced the closing of its initial public offering (the "Offering") of an aggregate of 1,403,685 ordinary shares, par value $0.001 per share (the "Ordinary Shares") at a public offering price of US$4.00 per share of which 1,000,000 Ordinary Shares were offered by the Company, and 403,685 Ordinary Shares were offered by certain selling shareholders of the Company. Hong Kong Pharma did not receive any proceeds from the sale of ordinary shares by the selling shareholders.

Charts implemented using Lightweight Charts™